Alnylam bulls and bears fight it out after business-shaking guidance cut
While Alnylam’s recent reduced revenue guidance spooked investors, analysts remain broadly bullish on the biotech’s commercial prospects.
Alnylam bulls and bears fight it out after business-shaking guidance cut Read More »
